Explore

Trendline Trendline
Bank of America Upgrades Moderna Following Significant Rally Driven by Cancer Vaccine Breakthrough

Bank of America Upgrades Moderna Following Significant Rally Driven by Cancer Vaccine Breakthrough

Bank of America Upgrades Moderna Following Significant Rally Driven by Cancer Vaccine Breakthrough
Rapid Read Rapid Read
Personalized mRNA Cancer Vaccine Shows Promise in Melanoma Trial

Personalized mRNA Cancer Vaccine Shows Promise in Melanoma Trial

Merck and Moderna announced that a personalized mRNA-based cancer vaccine, when combined with Merck's Keytruda, has shown significant success in a large, late-stage trial for high-risk melanoma patients. This combination regimen is the first to demonstrate the potential to extend the lifespans of melanoma patients whose cancer had been surgically removed. In Phase 3 trials, the treatment significantly reduced the risk of cancer returning or spreading. Earlier Phase 2b trials indicated a 49% reduction in melanoma recurrence and a 59% reduction in metastasization to distant organs. The vaccine works by using genetic information from a patient's individual tumor to identify and target the cancer's unique mutational fingerprint.
Trendline Trendline
Moderna and Merck Announce Promising Phase 3 Trial Results for Personalized mRNA Melanoma Vaccine

Moderna and Merck Announce Promising Phase 3 Trial Results for Personalized mRNA Melanoma Vaccine

Moderna and Merck Announce Promising Phase 3 Trial Results for Personalized mRNA Melanoma Vaccine
Rapid Read Rapid Read
Merck and Moderna Announce Promising Melanoma Vaccine Results

Merck and Moderna Announce Promising Melanoma Vaccine Results

Merck and Moderna have reported positive results for a new mRNA vaccine designed to prevent the recurrence of melanoma. According to the two pharmaceutical companies, the vaccine has enabled individuals with high-risk melanoma to experience longer periods without cancer recurrence. This development is being recognized by oncology experts as a significant step forward in cancer treatment. The vaccine leverages mRNA technology, a platform that gained prominence with COVID-19 vaccines, to target and potentially eliminate residual cancer cells, thereby reducing the likelihood of the disease returning. This approach represents a personalized medicine strategy, where the vaccine is tailored to the specific genetic mutations of a patient's tumor.
Rapid Read Rapid Read
Moderna and Merck's Personalized mRNA Melanoma Vaccine Shows Promising Results in Late-Stage Trial

Moderna and Merck's Personalized mRNA Melanoma Vaccine Shows Promising Results in Late-Stage Trial

Moderna and Merck have announced successful late-stage trial results for their personalized mRNA melanoma vaccine, intismeran. The vaccine, administered alongside Merck's immunotherapy drug Keytruda, significantly extended the time patients lived without their cancer returning or spreading, compared to Keytruda alone. This experimental treatment is custom-made for each patient, targeting the unique genetic mutations found in their tumor. The process involves sampling a patient's tumor, identifying its specific genetic sequence, and then incorporating this information into the vaccine's production. The vaccine is designed to train the patient's immune system to recognize and attack these cancerous cells. Earlier trials indicated a 49% reduced risk of cancer recurrence or spread. The latest Phase 3 trial results are a significant step towards potential FDA approval, offering new hope for patients with melanoma, the deadliest form of skin cancer.
Rapid Read Rapid Read
Moderna and Merck Melanoma Therapy Achieves Primary Goal in Phase 3 Trial, Shares Surge

Moderna and Merck Melanoma Therapy Achieves Primary Goal in Phase 3 Trial, Shares Surge

Moderna and Merck announced that their personalized mRNA cancer therapy, Intismeran Autogene combined with Merck’s Keytruda, met its primary endpoint in a Phase 3 melanoma trial. The trial, INTerpath-001, demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival for patients with high-risk stage IIB-IV melanoma whose tumors had been surgically removed. This marks the first positive Phase 3 readout for a personalized mRNA cancer therapy. Following the announcement, Moderna's shares surged by 93%, and Merck's shares increased by 7%. The companies plan to present detailed trial results at an upcoming international medical meeting and discuss regulatory submissions.
Reuters Reuters
Moderna shares double as cancer vaccine data rekindles investor hopes

Moderna shares double as cancer vaccine data rekindles investor hopes

By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock.
Reuters Reuters
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial

Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial

By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-stage trial when combined with Keytruda, sending the biotech's shares surging 90% in premarket trading.
Reuters Reuters
Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Rapid Read Rapid Read
Moderna and Merck Announce Promising Results for mRNA Cancer Vaccine in Melanoma Treatment

Moderna and Merck Announce Promising Results for mRNA Cancer Vaccine in Melanoma Treatment

Moderna and Merck have reported promising results from a late-stage trial of their mRNA cancer therapy, intismeran, combined with Merck’s pembrolizumab (Keytruda), for patients with melanoma. The study found that individuals who received the combination therapy experienced longer periods without cancer recurrence and fewer instances of cancer spreading, compared to those treated with Keytruda alone. Keytruda is the current standard treatment for melanoma. Moderna’s intismeran is still an experimental therapy, while Keytruda was first approved for melanoma in 2014. The trial included patients with stage 2 to stage 4 melanoma who had their tumors surgically removed.
Rapid Read Rapid Read
Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna have announced successful late-stage clinical trial results for their personalized mRNA cancer vaccine, intismeran, when combined with Merck’s Keytruda. The trial focused on adjuvant melanoma, where patients had their disease surgically removed. The drugmakers reported that the combination treatment significantly slowed the recurrence of melanoma and its spread to other parts of the body. This marks the first randomized Phase 3 clinical trial to definitively prove the benefit of neoantigen vaccines in cancer treatment. While detailed data has not yet been released, the preliminary findings suggest a promising new approach in oncology. The vaccine utilizes mRNA technology, which has also been instrumental in developing traditional vaccines and therapeutics.
Rapid Read Rapid Read
Moderna and Merck's Personalized mRNA Vaccine Shows Significant Promise Against Melanoma in Phase 3 Trial

Moderna and Merck's Personalized mRNA Vaccine Shows Significant Promise Against Melanoma in Phase 3 Trial

Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, successfully met its primary endpoints in a Phase 3 trial for high-risk melanoma. This marks the first time a personalized mRNA cancer therapy has reached this stage of success. The vaccine is custom-built from a sample of a patient's own tumor, designed to train the immune system to recognize specific mutations unique to that individual's cancer. In the trial, patients with high-risk melanoma who had undergone surgical removal of their tumors received either the vaccine in combination with Merck’s immunotherapy Keytruda, or Keytruda alone. The results showed that patients receiving the combination therapy experienced a longer period without cancer recurrence or spread, demonstrating statistically significant and clinically meaningful improvements. This builds upon earlier data that indicated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death with the ...